Cargando…
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631678/ https://www.ncbi.nlm.nih.gov/pubmed/35793454 http://dx.doi.org/10.1182/bloodadvances.2022007776 |
| _version_ | 1784823866740178944 |
|---|---|
| author | Rejeski, Kai Burchert, Andreas Iacoboni, Gloria Sesques, Pierre Fransecky, Lars Bücklein, Veit Trenker, Corinna Hernani, Rafael Naumann, Ralph Schäfer, Jonas Blumenberg, Viktoria Schmidt, Christian Sohlbach, Kristina von Bergwelt-Baildon, Michael Bachy, Emmanuel Barba, Pere Subklewe, Marion |
| author_facet | Rejeski, Kai Burchert, Andreas Iacoboni, Gloria Sesques, Pierre Fransecky, Lars Bücklein, Veit Trenker, Corinna Hernani, Rafael Naumann, Ralph Schäfer, Jonas Blumenberg, Viktoria Schmidt, Christian Sohlbach, Kristina von Bergwelt-Baildon, Michael Bachy, Emmanuel Barba, Pere Subklewe, Marion |
| author_sort | Rejeski, Kai |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9631678 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96316782022-11-04 Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy Rejeski, Kai Burchert, Andreas Iacoboni, Gloria Sesques, Pierre Fransecky, Lars Bücklein, Veit Trenker, Corinna Hernani, Rafael Naumann, Ralph Schäfer, Jonas Blumenberg, Viktoria Schmidt, Christian Sohlbach, Kristina von Bergwelt-Baildon, Michael Bachy, Emmanuel Barba, Pere Subklewe, Marion Blood Adv Research Letter American Society of Hematology 2022-08-16 /pmc/articles/PMC9631678/ /pubmed/35793454 http://dx.doi.org/10.1182/bloodadvances.2022007776 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Research Letter Rejeski, Kai Burchert, Andreas Iacoboni, Gloria Sesques, Pierre Fransecky, Lars Bücklein, Veit Trenker, Corinna Hernani, Rafael Naumann, Ralph Schäfer, Jonas Blumenberg, Viktoria Schmidt, Christian Sohlbach, Kristina von Bergwelt-Baildon, Michael Bachy, Emmanuel Barba, Pere Subklewe, Marion Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy |
| title | Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy |
| title_full | Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy |
| title_fullStr | Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy |
| title_full_unstemmed | Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy |
| title_short | Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy |
| title_sort | safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after cd19 car t-cell therapy |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631678/ https://www.ncbi.nlm.nih.gov/pubmed/35793454 http://dx.doi.org/10.1182/bloodadvances.2022007776 |
| work_keys_str_mv | AT rejeskikai safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT burchertandreas safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT iacobonigloria safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT sesquespierre safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT franseckylars safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT buckleinveit safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT trenkercorinna safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT hernanirafael safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT naumannralph safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT schaferjonas safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT blumenbergviktoria safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT schmidtchristian safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT sohlbachkristina safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT vonbergweltbaildonmichael safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT bachyemmanuel safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT barbapere safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy AT subklewemarion safetyandfeasibilityofstemcellboostasasalvagetherapyforseverehematotoxicityaftercd19cartcelltherapy |